Can This New Drug Boost Pfizer's Stock?
Pfizer's (NYSE: PFE) nasal spray Zavzpret was given the green light by the Food and Drug Administration earlier this month to treat patients with acute migraine. The company expects that the treatment will be available in pharmacies beginning in July.
With this approval, the pharmaceutical company now has an acute migraine treatment in nasal spray form to complement the oral treatment in its portfolio, Nurtec ODT. What could Zavzpret contribute to Pfizer's top line? Let's examine the phase 3 clinical trial results and the acute migraine market to gauge its sales potential.
Migraines tend to cause a pulsing or throbbing sensation on one side of the head. Along with this pain, patients can experience sensitivity to light, nausea, and vomiting during an episode. A migraine episode can last from a few hours to days.
Source Fool.com
